Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma

Hodgkin’s lymphoma (HL) is usually sensitive and curative to multi-agent chemotherapy, but may become refractory disease in a subset of relapsed patients. Recent novel agents, brentuximab-vedotin (BV) and immune checkpoint inhibitors have significantly improve the treatment outcome. We report the ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tsung-Ying, Dai, Ming-Shen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188374/
https://www.ncbi.nlm.nih.gov/pubmed/32362983
http://dx.doi.org/10.14740/jh596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188374/
https://www.ncbi.nlm.nih.gov/pubmed/32362983
http://dx.doi.org/10.14740/jh596

Ejemplares similares